Breaks Categories: Stock Spotlights

FridaySep 18, 2020 1:12 pm

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI), Helomics Provide Key Insight to Personalized Cancer Treatment

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine, lives by the motto: Cancer is personal; we believe therapy should be too. The company’s subsidiary Helomics builds AI-driven models designed to predict drug response and patient outcome of individual tumors. The company is able to do that because it relies on POAI’s tumor inventory, one of the largest in the world. POAI is a leader in working with oncologists in offering a functional precision medicine approach to treating cancer. Key information provided by Predictive Oncology can improve a patient’s odds in the fight against…

Continue Reading

TuesdaySep 15, 2020 12:43 pm

BioMedNewsBreaks – Why 180 Life Sciences Corp. Is ‘One to Watch’

180 Life Sciences, a clinical-stage biotechnology company, is focused on the development of novel drugs that fulfill unmet needs for a variety of conditions including fibrosis, pain and inflammatory diseases. 180 Life Sciences will soon form a combined company with KBL Merger Corp. (NASDAQ: KBLM) (KBL Merger Corp. Rights NASDAQ: KBLMR) (KBL Merger Corp. Warrant NASDAQ: KBLMW), a Special Purpose Acquisition Corporation (SPAC), with the new entity to be listed under ticker symbol “ATNF” on Nasdaq Capital Market. A recent article discussing the company reads, “180 Life Sciences is leading the research into solving one of the world’s biggest drivers…

Continue Reading

TuesdaySep 08, 2020 2:22 pm

BioMedNewsBreaks – Predictive Oncology Inc.’s (NASDAQ: POAI) Recent Board Appointments Combine Deep Experience, Expertise to Drive Strategic Vision

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine, recently announced board appointments to align expertise with the company’s strategic vision. These recently appointed board members — Dr. Nancy Chung-Welch, PhD; Charles L. Nuzum, CPA; and Greg St. Clair — bring to POAI more than a century of invaluable combined experience and life-science, business-development, marketing and financial expertise. An article discussing this quotes POAI CEO Dr. Carl Schwartz, who stated, “These appointments signify our absolute commitment to aligning our board’s expertise with the company’s strategic vision of developing and commercializing an offering that…

Continue Reading

WednesdaySep 02, 2020 2:25 pm

BioMedNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) CEO Discusses Transformation to B2B2C Digital Therapeutics

DarioHealth (NASDAQ: DRIO), a global digital-therapeutics company serving its users with dynamic mobile-health solutions, has recently achieved a series of successes and anticipates even more in the coming weeks. Among drivers of DRIO’s path toward leading cutting-edge solutions is the global pandemic, which has unveiled dynamics of the company’s business model that provide distinction in an era in need of next-generation health care. A recent article discussing this includes commentary from DarioHealth’s CEO Erez Raphael, who stated, “The COVID-19 pandemic has accelerated our ongoing transformation to a business-to-business-to-consumer (‘B2B2C’) digital therapeutics leader. We advanced late-stage discussions with health plans and…

Continue Reading

ThursdayAug 27, 2020 12:40 pm

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) and TumorGenesis Advancing Path Toward Patient-Specific Treatments

Predictive Oncology (NASDAQ: POAI), together with its TumorGenesis subsidiary, has achieved significant breakthroughs in applying data and artificial intelligence (“AI”) to personalized medicine and drug discovery. Earlier in June, TumorGenesis, which is developing a new rapid approach to growing tumors in the laboratory, sold its first order of unique ovarian cancer cell culture media to a New England-based university carrying out research within the sector (http://ibn.fm/lpsCk). A recent article discussing POAI and TumorGenesis reads, “Predictive Oncology focuses on building AI-driven predictive models of tumor drug response and outcomes from its database of drug-response and genomic profiles gathered from more than 150,000…

Continue Reading

WednesdayAug 26, 2020 2:13 pm

BioMedNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Positioned to Compete in ‘Largely Untapped US Market’

DarioHealth (NASDAQ: DRIO), a global digital-therapeutics company serving its users with dynamic mobile-health solutions, recently completed a round of successful fundraising that will assist in expanding the availability of its platform. DarioHealth secured approximately $28.6 million in aggregate gross proceeds from health-care funds and institutions across the United States and Israel through the private-placement transaction with accredited investors. The new capital coupled with existing cash  puts the company in its best financial state since its inception (http://ibn.fm/uKWvc). A recent article discussing this quotes Dario CEO Erez Raphael, who stated, “We are pleased to have the confidence of our largest shareholder and…

Continue Reading

WednesdayAug 19, 2020 12:37 pm

BioMedNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Taking Health Care Home Through Innovative Platform

DarioHealth (NASDAQ: DRIO), a global digital-therapeutics company serving its users with dynamic mobile-health solutions, is a clear point-of-need innovator in today’s standoffish environment. The company supplies hospitals with next-generation technology to provide patients necessary care as they are “roomed” at home under a remote-monitoring regimen. A recent article discussing this reads, “DarioHealth’s Remote Patient Monitoring (‘RPM’) digital therapeutics platform provides physicians with essential information and also delivers occasional ‘nudges’ to patients when its automated programming recognizes a need (http://ibn.fm/tC5si).” To view the full article, visit http://ibn.fm/cyAME About DarioHealth Corp. DarioHealth is a leading, global, digital-therapeutics company revolutionizing the way people with…

Continue Reading

FridayAug 07, 2020 1:23 pm

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Marks Milestone in Applying AI to Find New Targets for Treatment, Diagnostics

Predictive Oncology (NASDAQ: POAI), through its subsidiary TumorGenesis and working with distributor US Biological Corporation, has accomplished a major achievement. Recently, the company announced its first-ever commercial order of a novel ovarian cancer cell culture media for cancer cells collected from patient-derived samples (“PDx”) (http://ibn.fm/2xwl6). An article discussing this quotes Richard Gabriel of TumorGenesis, who states, “Capturing and culturing and then being able to study ovarian cancer cell types has always been limited by the ability to grow reproducible cultures that reflect what is in the patient. We now have isolated and grown 25 ovarian cancer cell types, 11 of that…

Continue Reading

ThursdayJul 30, 2020 2:02 pm

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) to Integrate Proprietary Database with CoRE to Drive Drug Discovery, Development

Predictive Oncology (NASDAQ: POAI) has completed a strategic move to accelerate commercialization of its proprietary artificial intelligence “AI”-driven drug discovery and development. A recent article discussing Predictive Oncology’s recent acquisition of Quantitative Medicine (“QM”), a biomedical analytics and computational biology company, quotes POAI CEO Dr. Carl Schwartz, where he states, “This acquisition will enable us to further leverage our unique database of drug-response and genomics profiles that our subsidiary, Helomics, has gathered from more than 150,000 cancer cases over more than 10 years of clinical testing. Integrating QM’s proven machine-learning platform, CoRE, with our proprietary database of drug response and…

Continue Reading

MondayJul 27, 2020 2:30 pm

BioMedNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) to Deliver Best-In-Class RPM Solution Across the United Kingdom and Ireland

DarioHealth (NASDAQ: DRIO), a global digital-therapeutics company serving its users with dynamic mobile-health solutions, will begin serving Europeans with its health-monitoring solution through a strategic partnership with Williams Medical. Under the partnership, the DarioHealth Remote Patient Monitoring (“RPM”) digital therapeutics platform will be made available to healthcare professionals across the United Kingdom and Ireland. A recent article quotes DarioHealth COO Dror Bacher on this move, where Bacher states, “We are very excited about this partnership between DarioHealth and Williams Medical as this aligns with our international growth initiative by offering our world-class RPM platform to physicians outside of the United…

Continue Reading